The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
MarketWatch · Mon, 26 Oct 2026 13:50:00 GMT
Read the full story at MarketWatch ↗OmniFin Portal's take
Excerpt from MarketWatch: “Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.”
Rule-based headline sentiment: Neutral
More Stocks headlines
Microsoft stock jumps 4% as cloud growth drives earnings and revenue beat— CNBC MarketsBillionaire Ambani cries tears of joy as Jio Platforms becomes the second most valued Indian firm— CNBC MarketsOver 41,000 U.S. Homeland Security officials' details apparently exposed after massive data breach— CNBC MarketsTrump methane policy rollback may have minimal impact on crude prices, EPA says— CNBC Markets